A randomized trial of vorinostat with treatment interruption after initiating antiretroviral therapy during acute HIV-1 infection
Eugene DMD Kroon, Jintanat Ananworanich, Amelie Pagliuzza, Ajantha Rhodes, Nittaya Phanuphak, Lydie Trautmann, Julie L Mitchell, Michelle Chintanaphol, Jintana Intasan, Suteeraporn Pinyakorn, Khuntalee Benjapornpong, J Judy Chang, Donn J Colby, Nitiya Chomchey, James LK Fletcher, Keith Eubanks, Hua Yang, John Kapson, Ashanti Dantanarayana, Surekha Tennakoon Show all
Journal of Virus Eradication | MEDISCRIPT LTD | Published : 2020
Awarded by Henry M Jackson Foundation for the Advancement of Military Medicine, Inc.
Awarded by US Department of the Army
Awarded by National Institute of Neurologic Disorders and Stroke
Awarded by federal funds from the National Cancer Institute, National Institutes of Health
Awarded by National Institute of Allergy and Infectious Diseases
Awarded by National Health and Medical Research Council of Australia (NHMRC Program)
Awarded by National Institutes for Health Delaney AIDS Research Enterprise
We would like to thank the study participants who committed so much of their time for this study. The participants were from the RV254 acute HIV infection study, which is supported by cooperative agreements (W81XWH-07-2-0067, W81XWH-11-2-0174) between the Henry M Jackson Foundation for the Advancement of Military Medicine, Inc., and the US Department of the Army and by an intramural grant from the Thai Red Cross AIDS Research Centre. The US Army Medical Research Acquisition Activity (820 Chandler Street, Fort Detrick, MD 21702-5014, USA) is the awarding and administering acquisition office for the cooperative agreement. Antiretroviral therapy for RV254 participants was supported by the Thai Government Pharmaceutical Organization, Gilead, Merck and ViiV Healthcare. This work was also funded in part by 1R01NS084911-01 from the National Institute of Neurologic Disorders and Stroke and with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E and by 1R01AI108433 from the National Institute of Allergy and Infectious Diseases. SRL, JJC, AR, AD and ST are supported by National Health and Medical Research Council of Australia (NHMRC Program Grant GNT1052979) and the National Institutes for Health Delaney AIDS Research Enterprise (DARE AI096109 and AI126611), and the American Foundation for AIDS Research. SRL is an NHMRC practitioner fellow.We thank Brandie A. Fullmer for work on the single-copy HIV RNA assay. We thank the staff from SEARCH and the HIV-NAT laboratory at the Thai Red Cross AIDS Research Centre for their valuable contributions to this study. We also thank Cooper Human Systems, Nashua, NH, USA for providing funding for vorinostat.